ERBB2 and breast cancer: Sensitivity analysis and publication bias suggested that the results were stable and reliable.<h4>Conclusion</h4>Statistically significant benefits for PFS and OS were observed with ADCs in HER2-positive locally advanced or metastatic BC, especially for those who received prior anti-HER2 treatment.